EGFR and lung adenocarcinoma: It is well known that mutations of the epidermal growth factor receptor (EGFR) gene are present in some patients with lung adenocarcinoma, with the implication that patients with this genotype were super responders to EGFR-tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib.